Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : AMERICAN BIOMED, Minimally Invasive Technology (ABMI) -- Ignore unavailable to you. Want to Upgrade?

To: priceguy who wrote (543)	4/23/1998 11:19:00 PM
From: Y2k_fan	Respond to of 2887

Count me in. ABMI will have a bright future.

To: priceguy who wrote (543)	4/24/1998 12:51:00 AM
From: Jeffrey L. Henken	Read Replies (1) \| Respond to of 2887

There are billions of dollars out there looking for a competitive advantage. I could pick any number of companies but I will take some recent comments from an article on Aterial Vascular Engineering who just recently bought World Medical Corporation and some comments from JNJ's press release today outlining their growth strategies to make my points: First an excerpt from that recent article on AVEI: investor.msn.com Most analysts are estimating a 1998 U.S. stent market at about $1.2 to $1.3 billion with a worldwide estimate of $1.9 billion. What has caused such phenomenal growth from just $700 million in 1997? Clearly, it's been the introduction of second-generation stents, which allow cardiologists to more aggressively treat diseases that were previously not manageable with conservative catheter-based therapies. Being able to place these devices in lesions where the older Johnson & Johnson (JNJ) stents would not go is the key to the market's exploding growth. It is estimated that J&J will end up with a 10% market share this year, whereas just two years ago in 1996, it had share greater than 90%. Almost $2 billion dollars will be made in the stent market this year. To AVEI a price tag of 62 million for World Medical must have seemed a real good buy to protect their market share. So what about companies like JNJ who are striving to regain market share in the minimally invasive surgery field? Well they have new products coming out, loads of money being spent on research and all their patents to protect them but they also admit one more thing in today's report which reads as follows: The others, he noted, are to continue to aggressively pursue licensing, outside investment and acquisition opportunities; as well as maintaining a commitment to productivity and cost efficiency. biz.yahoo.com You know I really hope American BioMed gets the chance to develop into it's own company but it may not happen. There is simply too much competition between the big players in the minimally invasive surgery field for me to believe that someone with deep pockets will not to want to have a chance to use American BioMed's technology and patents to their advantage. Thanks everyone for your kind words and support! GO ABMI! Regards, Jeff